// App-Quantinova.ai

DOP004 : Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY

Researchers

Presenter

  • P Bossuyt

Principal Investigators

  • R Atreya

  • C Taxonera

  • X Hebuterne

  • K Isaacs

  • P D Higgins

  • J Lindsay

  • G Heap

  • D Arikan

  • V Kuehnl

  • J Petersson

  • A M Robinson

  • E V Loftus, Jr

Medical Centers

  • Imelda Hospital, Bonheiden, Belgium

  • Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany

  • Hospital Clínico San Carlos, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Madrid, Spain

  • IdISSC - Instituto de Investigacion Sanitaria San Carlos, Madrid, Spain

  • Service de Gastroentérologie et Nutrition Clinique, Nice, France

  • Universite Nice Sophia-Antipolis, Nice, France

  • University of North Carolina, Department of Medicine, Division of Gastroenterology and Hepatology, Chapel Hill, USA

  • University of Michigan, Ann Arbor, MI

  • Queen Mary University of London, Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, London, UK

  • AbbVie, Inc., North Chicago, IL

  • AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

  • Mayo Clinic, Gastroenterology and Hepatology, Rochester, MN

Locations

  • Belgium

  • Germany

  • Spain

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved